- AdventHealth
Collaborative Clinical Outcomes Research Article Published in Gynecologic Oncology
Nnamdi Gwacham, MD
Robert W. Holloway, MD
Nathalie D. McKenzie, MD
Sarfraz Ahmad, MD
Gynecologic Oncology Program
AdventHealth Cancer Institute
Nnamdi I. Gwacham1, Nathalie D. McKenzie1,2, Evan Fitzgerald2, Sarfraz Ahmad1,2, Robert W. Holloway1,2
1AdventHealth Cancer Institute, Gynecologic Oncology Program, and 2Florida State University, College of Medicine, Orlando, FL. 32804
Summary
Background: Approach to the management of early-stage cervical cancers with tumor size >2 cm in women who desire fertility preservation has been fraught with controversy. Fertility sparing surgery for FIGO 2018 stage IB cancers has been validated most for tumors ≤ 2 cm. In this review, our objective was to evaluate the oncologic and obstetric outcomes for women that underwent neoadjuvant chemotherapy (NACT) before fertility sparing surgery for tumors 2-4 cm.
Methods: We performed a systematic literature review and searched PubMed, Google Scholar, Cochrane Reviews and UpToDate (from January 2000 to February 2021) using the terms: cervical cancer, fertility preservation, trachelectomy, radical trachelectomy, neoadjuvant chemotherapy, cervical cancer treatment, stage IB1 or IB2 cervical cancer, and cervical cancer size 2-4 cm. We included manuscripts with information on patients with tumor sizes 2-4 cm, lymph node status, follow-up, obstetric and oncologic outcome. We excluded review articles or articles without all pertinent patient information.
Results: Eighteen articles were identified including 249 patients. For final analysis, 114 cases met inclusion criteria. All included patients had FIGO 2018 stage IB2 cervical cancer, underwent neoadjuvant chemotherapy and subsequent fertility sparing surgery. Vaginal radical trachelectomy, cold knife conization, abdominal radical trachelectomy, laparoscopic radical trachelectomy, simple vaginal trachelectomy, and cone laser were performed in 46 (40.4%), 26 (22.8%), 14 (12.3%), 13 (11.4%), 8 (7%), and 7 (6.1%) women, respectively. The most common regimen of chemotherapy was platinum-based therapy with cisplatin. The follow-up time reported in all studies ranged from 1 to 225 months. Of 64 attempted pregnancies, there were 49 (76.6%) viable deliveries which included six preterm births (9.4%). The recurrence rate was 6.1%, and two patients (1.8%) died of disease.
Conclusion: Fertility sparing surgery following NACT is an option for women with cervical cancers that are 2-4 cm who wish to preserve fertility without sacrificing oncologic or obstetric outcomes. Confirmation of these findings are anticipated from an ongoing international Phase II clinical trial.
Highlights
- Response rate to neoadjuvant chemotherapy is 92% for cervical cancer 2-4 cm.
- Recurrence rate is 6.1% after neoadjuvant chemotherapy and fertility sparing surgery.
- Obstetric outcomes appear to be favorable in this subset of patients.
For more information or to refer a patient, call GYN Oncology Nurse Navigator Althea Buckner, MSN, APRN-AOCNP, at Call407-303-5909.
Recent News
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...
Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...
AdventHealth East Orlando recently became the first hospital in Florida to earn Advanced Foot & Ankle Surgery Certification from DNV, a worldwide, independent certification body.
With an aging population and increases in the prevalence of neurological conditions like Alzheimer’s disease and dementia, physicians and patients alike continue to seek new tools and approaches to...
In a new article published in the medical journal Age and Ageing, AdventHealth Research Institute’s Dr. Audrey Collins shares the results of a recent study evaluating the impact of exercise on...
The AdventHealth Neuroscience Institute is the first in Florida and one of the first in the country to begin recruiting patients with primary progressive or non-active secondary progressive multiple...
Accurately determining food intake remains a challenge in nutrition research. A new study published in Nature Metabolism and co-authored by Dr. Corbin introduces a metagenomics-powered approach to...
Discover what’s being accomplished in Central Florida to bridge the health gap with Orange County Mayor Jerry Demings and AdventHealth’s Dr. Alric Simmonds.
Breakthrough device offers new hope for stroke survivors struggling with rehabilitation following ischemic stroke